Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Economic information and modeling reportBudget impact model

Budget impact model discussion

2 evidence topics · 8 sources

Summary

No budget impact model of lorundrostat from Mineralys or a health plan was identified; the only budget impact analysis is ICER's potential budget impact analysis in its 2026 evidence report, which uses a placeholder price of $10,950 per year equal to the baxdrostat wholesale acquisition cost ($900 for 30 tablets). The analysis takes the cost-effectiveness model's health care costs, undiscounted, over five years, against an even split of spironolactone, eplerenone, and amiloride, whose median generic acquisition costs in ICER's model were $43 to $1,022 per year. It sized 10,042,828 United States adults with resistant hypertension on three or more drugs (Population 1) and 2,516,732 on two drugs who discontinued a third (Population 2, based on a 21% placeholder discontinuation estimate), 12,559,560 in total, and assumed 20% would initiate treatment in each year. At the placeholder price, the cumulative budget impact per patient treated was about $8,500 in year one and $16,300 by year five, and about 2% of eligible patients could be treated before annual spending reached ICER's threshold of $821 million; at the threshold prices, 100% could be treated against eplerenone and at the $50,000 per evLY prices against spironolactone ($630) and amiloride ($810). ICER did not size Population 3, patients on two drugs who have not tried a third, which overlaps the company's stated “third line or later” target. The analysis reports national figures and does not model a health plan membership; a 2026 poster hosted on the Mineralys website estimates, for a hypothetical 1 million–member plan, 194,140 treated adults with hypertension, 104,494 with uncontrolled hypertension, and 37,081 receiving three or more drugs. The actual budget impact will depend on a lorundrostat price not yet announced (Mineralys has referred to an SGLT2 inhibitor or Entresto price point at WAC and has given no rebate guidance), on rebates, and on displacement of baxdrostat, whose NADAC was $28.78424 per 2 mg tablet on 18 November 2026, and of generic mineralocorticoid receptor antagonists and amiloride, whose NADAC ranged from $0.04218 to $0.47438 per tablet.